Predict your next investment

HEALTHCARE | Pharmaceutical Distribution & Wholesale

See what CB Insights has to offer

Founded Year



Acquired | Acquired

About Genepharm

Genepharm is focused on the development, manufacturing and marketing of generic pharmaceuticals.

Genepharm Headquarter Location

18km Marathon Avenue

Pallini, 15351,


+30 210 603 9336

Latest Genepharm News

MS Pharma acquires Genepharm, expands chronic disease portfolio

Apr 23, 2019

Jordan-based MS Pharma announces the acquisition of the Greek generic manufacturer Genepharm, aiming to add cardiovascular, CNS and oncology products to its portfolio. Genepharm develops, manufactures and out-licenses generic pharmaceutical products, focusing on conventional solids, sterile liquid and oncology oral solids, for a client base across 70 countries. MS Pharma, which operates across the Middle East, Turkey and Africa, will acquire 100% of Genepharm’s shares, while it also announced plans to ‘significantly increase’ Genepharm’s development resources in Athens. According to MS Pharma, through the acquisition the company aims to expand its geographic footprint and reach more customers in Europe. In addition, MS Pharma intends to bolster its portfolio with cardiovascular, CNS and oncology products, while it stated that Genepharm's portfolio will be strengthened with sterile injectable products and biotechnology candidates. According to the agreement, Genepharm’s management will remain with the business. The transaction is expected to close by the end of April 2019. The cost of MS Pharma’s investment was not disclosed. MS Pharma employs over 2,000 people in its facilities in Algeria, Jordan, Saudi Arabia and Turkey and exports to over 20 countries. Copyright - Unless otherwise stated all contents of this web site are © 2019 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.